Problem.
Decreasing energy levels, lower metabolism, age related disease, etc etc (one or two paragraphs on describe aging problems that NMN solves, ideally from two angles: aging symptoms that people experience [e.g. cognitive decline] and from either the aging theories or biological mechanisms angle)
A compound that can help us solve this - NAD precursors, particularly - Nicotinamide Mononucleotide
If there is no solid scientific data on NMN on humans, consider giving a side-by-side comparison of Nicotinamide Riboside and NMN on the parameters listed below
Possibly write up on that there are three NAD boosters currently in Phase I clinical trials. If they are established safe, they will move to Phase II (efficacy studies). Then Phase III. Than they will be officially proclaimed as effective drugs.
What it is. Also known as β-NMN, NAMN, NMN
How it works
What it does
Limitations, what we do not yet know.
Dose. How fast it acts. Half-life. Interactions. Form (if there are different forms of it)
On the dose - give breakdown on what we have. Rodent dose that was found effective, including info on the duration of the administration. Human dose in the clinical trials.
Interactions info - Resveratrol and any other known interactions
Summary: recommended regimen - how much, how often, combined with what
Comparison with Nicotinamide Riboside
Maybe, in a table format compare side by side, level of evidence, effects, doses, half life etc
To read only, not to reference.
https://www.elysiumhealth.com/en-us/knowledge/science-101/nmn-and-nr-how-these-nad-precursors-measure-up
https://www.leafscience.org/david-sinclair-ama/
Maybe one paragraph on Sinclair's regimen - what and how much he takes
Information sources for references:
Published on NCBI only (no blogs or write ups from non-peer reviewed publications).
Here are some, look for more (I am using AMA citation format)
REFERENCES
Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9(1):34. Published 2019 Jan 21. doi:10.3390/biom9010034
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359187/
Part 4 has data on comparison of NMN to Nicotinamide Riboside, including references to the original studies.
https://www.ncbi.nlm.nih.gov/pubmed/27725413
Brazill JM, Li C, Zhu Y, Zhai RG. NMNAT: It's an NAD+ synthase… It's a chaperone… It's a neuroprotector. Curr Opin Genet Dev. 2017;44:156–162. doi:10.1016/j.gde.2017.03.014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515290/
Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. Published 2018 Mar 29. doi:10.1038/s41467-018-03421-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/
Wei CC, Kong YY, Li GQ, Guan YF, Wang P, Miao CY. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci Rep. 2017;7(1):717. Published 2017 Apr 6. doi:10.1038/s41598-017-00851-z
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429727/
Decreasing energy levels, lower metabolism, age related disease, etc etc (one or two paragraphs on describe aging problems that NMN solves, ideally from two angles: aging symptoms that people experience [e.g. cognitive decline] and from either the aging theories or biological mechanisms angle)
A compound that can help us solve this - NAD precursors, particularly - Nicotinamide Mononucleotide
If there is no solid scientific data on NMN on humans, consider giving a side-by-side comparison of Nicotinamide Riboside and NMN on the parameters listed below
Possibly write up on that there are three NAD boosters currently in Phase I clinical trials. If they are established safe, they will move to Phase II (efficacy studies). Then Phase III. Than they will be officially proclaimed as effective drugs.
What it is. Also known as β-NMN, NAMN, NMN
How it works
What it does
Limitations, what we do not yet know.
Dose. How fast it acts. Half-life. Interactions. Form (if there are different forms of it)
On the dose - give breakdown on what we have. Rodent dose that was found effective, including info on the duration of the administration. Human dose in the clinical trials.
Interactions info - Resveratrol and any other known interactions
Summary: recommended regimen - how much, how often, combined with what
Comparison with Nicotinamide Riboside
Maybe, in a table format compare side by side, level of evidence, effects, doses, half life etc
To read only, not to reference.
https://www.elysiumhealth.com/en-us/knowledge/science-101/nmn-and-nr-how-these-nad-precursors-measure-up
https://www.leafscience.org/david-sinclair-ama/
Maybe one paragraph on Sinclair's regimen - what and how much he takes
Information sources for references:
Published on NCBI only (no blogs or write ups from non-peer reviewed publications).
Here are some, look for more (I am using AMA citation format)
REFERENCES
Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9(1):34. Published 2019 Jan 21. doi:10.3390/biom9010034
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359187/
Part 4 has data on comparison of NMN to Nicotinamide Riboside, including references to the original studies.
https://www.ncbi.nlm.nih.gov/pubmed/27725413
Brazill JM, Li C, Zhu Y, Zhai RG. NMNAT: It's an NAD+ synthase… It's a chaperone… It's a neuroprotector. Curr Opin Genet Dev. 2017;44:156–162. doi:10.1016/j.gde.2017.03.014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515290/
Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. Published 2018 Mar 29. doi:10.1038/s41467-018-03421-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/
Wei CC, Kong YY, Li GQ, Guan YF, Wang P, Miao CY. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci Rep. 2017;7(1):717. Published 2017 Apr 6. doi:10.1038/s41598-017-00851-z
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429727/